Triangle Securities Wealth Management Sells 196 Shares of Bristol-Myers Squibb (NYSE:BMY)

Triangle Securities Wealth Management decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 0.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 39,456 shares of the biopharmaceutical company’s stock after selling 196 shares during the quarter. Triangle Securities Wealth Management’s holdings in Bristol-Myers Squibb were worth $2,335,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. ProShare Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 16.4% during the 2nd quarter. ProShare Advisors LLC now owns 422,937 shares of the biopharmaceutical company’s stock valued at $28,261,000 after purchasing an additional 59,611 shares during the last quarter. Biondo Investment Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 5.0% during the 2nd quarter. Biondo Investment Advisors LLC now owns 96,114 shares of the biopharmaceutical company’s stock valued at $6,422,000 after purchasing an additional 4,608 shares during the last quarter. Taylor Frigon Capital Management LLC boosted its position in Bristol-Myers Squibb by 8.7% during the 2nd quarter. Taylor Frigon Capital Management LLC now owns 20,395 shares of the biopharmaceutical company’s stock valued at $1,363,000 after buying an additional 1,639 shares during the period. Kentucky Retirement Systems purchased a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $8,692,000. Finally, Rafferty Asset Management LLC boosted its position in Bristol-Myers Squibb by 10.6% during the 2nd quarter. Rafferty Asset Management LLC now owns 53,717 shares of the biopharmaceutical company’s stock valued at $3,589,000 after buying an additional 5,132 shares during the period. 72.07% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE BMY opened at $56.81 on Thursday. The firm has a 50 day moving average of $58.78 and a 200 day moving average of $63.83. The company has a current ratio of 1.47, a quick ratio of 1.36 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $126.10 billion, a price-to-earnings ratio of -23.67, a price-to-earnings-growth ratio of 1.08 and a beta of 0.61. Bristol-Myers Squibb has a 12-month low of $56.11 and a 12-month high of $69.75.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Tuesday, October 26th. The biopharmaceutical company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.08. The company had revenue of $11.62 billion during the quarter, compared to analyst estimates of $11.52 billion. Bristol-Myers Squibb had a negative net margin of 11.89% and a positive return on equity of 43.05%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.63 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 7.52 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, November 1st. Shareholders of record on Friday, October 1st were issued a dividend of $0.49 per share. This represents a $1.96 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend was Thursday, September 30th. Bristol-Myers Squibb’s dividend payout ratio is currently -81.67%.

In other Bristol-Myers Squibb news, EVP Autenried Paul Von sold 17,353 shares of the business’s stock in a transaction on Wednesday, November 24th. The shares were sold at an average price of $56.92, for a total transaction of $987,732.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Giovanni Caforio sold 25,000 shares of the business’s stock in a transaction on Monday, September 20th. The shares were sold at an average price of $60.64, for a total transaction of $1,516,000.00. The disclosure for this sale can be found here. Insiders have sold 60,716 shares of company stock worth $3,553,545 in the last ninety days. Insiders own 0.11% of the company’s stock.

Several research firms have recently commented on BMY. Bank of America reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, July 28th. BMO Capital Markets began coverage on shares of Bristol-Myers Squibb in a research report on Thursday, November 18th. They set an “outperform” rating and a $72.00 price target for the company. Truist Securities began coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, July 28th. They set a “buy” rating and a $74.00 price target for the company. Truist began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, July 28th. They set a “buy” rating and a $74.00 price objective for the company. Finally, TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b” rating in a research note on Wednesday, November 17th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average target price of $69.20.

About Bristol-Myers Squibb

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Recommended Story: Gap Down Stocks

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.